| language |
eng
|
| Author |
M. Shiraki
Research Institute and Practice for Involutional Diseases, 1610-1 Misatomeisei, Azumino, Nagano, 399-8101, Japan
Fukunaga M.
Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan
Kishimoto H.
Nojima Hospital, 2714-1 Sesakimachi, Kurayoshi, Tottori, 682-0863, Japan
Hagino H.
School of Health Science, Tottori University, 86 Nishicho, Yonago, Tottori, 683-8503, Japan
Sone T.
Department of Nuclear Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan
Nakano T.
Tamana Central Hospital, 1950 Naka, Tamana, Kumamoto, 865-0064, Japan
Ito M.
Center for Diversity and Inclusion, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8520, Japan
Yoshikawa H.
Department of Orthopaedic Surgery, Graduated School of Medicine, Osaka University, 1-1 Yamadaoka, Suita, Osaka, 565-0871, Japan
Minamida T.
Asahi Kasei Pharma Corporation, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo, 100-0006, Japan
Tsuruya Y.
Asahi Kasei Pharma Corporation, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo, 100-0006, Japan
Nakamura T.
Toto Sangenjaya Rehabilitation Hospital, 1-24-3 Sangenjaya, Setagaya-ku, Tokyo, 154-0024, Japan
|
| Subject | Teriparatide; Osteoporosis; Bone mineral density; Safety; Twice-weekly; Randomized controlled trial
|
| Journal Title |
OSTEOPOROSIS INTERNATIONAL
|
| Volume | 30
|
| Issue | 11
|
| Start Page | 2321
|
| End Page | 2331
|
| ISSN | 0937-941X
|
| ISSN（Online） | 1433-2965
|
| Published Date | 2019-11
|
| DOI | |
| PubMed ID | |
| Publisher | SPRINGER LONDON LTD
|
| NII Type |
Journal Article
|
| OAI-PMH Set |
Faculty of Medicine
|
| Remark | The study was sponsored and funded by the Asahi Kasei Pharma Corporation, Tokyo, Japan. The sponsor had responsibility for quality control. The corresponding author had full access to all of the data in the study and had responsibility for the decision to submit for publication.; The study was jointly designed by the authors and the sponsor, Asahi Kasei Pharma Corporation. The authors discussed the interpretation of the data and the conclusions of the manuscript with the sponsor. Data analyses for publication were the responsibilities of the sponsor. ToS has received research grants from Astellas Pharma, Eisai, Daiichi-Sankyo, Chugai Pharmaceutical, and Eli Lilly Japan, as well as consulting and/or lecture fees from Asahi Kasei Pharma and Daiichi-Sankyo. MS has received consulting fees from Asahi Kasei Pharma, Chugai Pharmaceutical and Teijin Pharma. HK has received consulting fees from Asahi Kasei Pharma, Chugai Pharmaceutical, Daiichi-Sankyo and EA Pharma. HH has received consulting fees for this study from Asahi Kasei Pharma and lecture fees or grants outside the submitted work from Asahi Kasei Pharma, Astellas Pharma, Chugai Pharmaceutical, Eisai, Eli Lilly Japan, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Ono Pharmaceutical, Pfizer, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, Teijin Pharma and Daiichi-Sankyo. TeS has received research grants from Asahi Kasei Pharma, Astellas Pharma, Kissei Pharmaceutical, Pfizer, Taisho Toyama Pharmaceutical and Takeda Pharmaceutical. TeN has received consulting fees from Asahi Kasei Pharma. MI has received research grants from Asahi Kasei Pharma, Astellas Pharma, Chugai Pharmaceutical and Daiichi-Sankyo. TM is an employee of Asahi Kasei Pharma. YT is an employee of Asahi Kasei Pharma. ToN has received consulting fees from Asahi Kasei Pharma and Chugai Pharmaceutical, and speaker fees from Daiichi-Sankyo and Taisho Toyama Pharmaceutical.
|
